Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK13 | O15264 | 3/20 | 0.55 |
| ▸ | BRAF | P15056 | 13/20 | 0.55 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.55 |
| ▸ | ABL1 | P00519 | 3/20 | 0.52 |
| ▸ | AXL | P30530 | 1/20 | 0.52 |
| ▸ | SRC | P12931 | 2/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5060048 | 0.92 | MAPK13 (0.58) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5054828 | 0.90 | MAPK14 (0.58) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5062000 | 0.89 | MAP3K7 (0.61) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5062147 | 0.88 | BRAF (0.62) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5054612 | 0.88 | MAPK13 (0.55) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5060009 | 0.85 | ABL1 (0.58) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5062447 | 0.85 | MAPK13 (0.59) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5052361 | 0.85 | BRAF (0.46) | MAPK13BRAFMAPK14AXLRAF1 | |
| SCHEMBL5052992 | 0.85 | ABL1 (0.56) | MAPK13BRAFMAPK14ABL1AXL | |
| SCHEMBL5054904 | 0.85 | MAPK14 (0.61) | MAPK13BRAFMAPK14ABL1AXL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | DECIPHERA PHARMACEUTICALS, LLC (US) | 2008-05-15 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080113967-A1 | ENZYME MODULATORS AND TREATMENTS | ABL2, BRAF, MAP3K1 | MAPK13 118/4885BRAF 2/4885MAPK14 100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.